Search

Displaying results 3981 - 3990 of 10000 in total
  1. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions.

    Mixtures: Darvocet-N 50, Darvocet-N 100Products: Darvon-N
  2. Drug

    Lanolin alcohols

    go.drugbank.com/drugs/DB14181
    Approved

    Lanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin.

  3. Drug

    Dichlorobenzene

    go.drugbank.com/drugs/DB14046
    ApprovedWithdrawn

    Dichlorobenzene refers to any of, or a mixture of, three isomers consisting of benzene in which two of the hydrogen atoms are replaced by chlorine atoms: ortho-, meta-, and paradichlorobenzene.

  4. Drug

    Velaglucerase alfa

    go.drugbank.com/drugs/DB06720
    Approved

    Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase.

  5. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1. … [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.

  6. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542] … [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

  7. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    Tanaproget (NSP-989) is an investigational non-steroidal progestin. … Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals.

  8. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial. … CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.

  9. Drug

    Encenicline

    go.drugbank.com/drugs/DB11726
    Investigational

    Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.

  10. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.